H.C. Wainwright Reiterates a Buy Rating on Protalix Biotherapeutics (PLX)


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Protalix Biotherapeutics (PLX), with a price target of $11.00. The company’s shares closed last Friday at $3.62.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.5% and a 63.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Biospecifics Technologies, and Springworks Therapeutics.

Protalix Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.87 and a one-year low of $2.04. Currently, Protalix Biotherapeutics has an average volume of 92.77K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company’s drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts